脑转移瘤多区域影像组学可预测转移性NSCLC的EGFR-TKI疗效
研究纳入230例原发队列和80例外部队列的NSCLC脑转移患者,基于增强T1和T2 MRI提取肿瘤活性区与瘤周水肿区影像组学特征,构建预测EGFR突变和EGFR-TKI疗效的组学标签。多区域联合标签预测EGFR突变的外部验证AUC为0.889,预测TKI疗效的外部验证AUC为0.808。
要点
- 多区域联合影像组学标签预测EGFR突变外部验证AUC达0.889。
- 多区域联合标签预测EGFR-TKI疗效外部验证AUC为0.808。
- 肿瘤活性区与瘤周水肿区信息互补,联合建模性能最优。
诊断标准与关键数值
- 预测EGFR突变:RS-EGFR-Com在原发训练、内部验证和外部验证队列的AUC分别为0.896、0.856和0.889。
- 预测EGFR-TKI疗效:RS-TKI-Com在原发训练、内部验证和外部验证队列的AUC分别为0.817、0.788和0.808。
临床应用与阅片要点
- 阅片时可同时关注肿瘤活性区和瘤周水肿区,二者对TKI疗效预测具有互补信息。
- 多区域联合影像组学标签可作为分层工具,辅助筛选可能从EGFR-TKI治疗中获益的脑转移患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop radiomics signatures from multiparametric magnetic resonance imaging (MRI) scans to detect epidermal growth factor receptor (EGFR) mutations and predict the response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC) patients with brain metastasis (BM).
METHODS: We included 230 NSCLC patients with BM treated at our hospital between January 2017 and December 2021 and 80 patients treated at another hospital between July 2014 and October 2021 to form the primary and external validation cohorts, respectively. All patients underwent contrast-enhanced T1-weighted (T1C) and T2-weighted (T2W) MRI, and radiomics features were extracted from both the tumor active area (TAA) and peritumoral edema area (POA) for each patient. The least absolute shrinkage and selection operator (LASSO) was used to identify the most predictive features. Radiomics signatures (RSs) were constructed using logistic regression analysis.
RESULTS: For predicting the EGFR mutation status, the created RS-EGFR-TAA and RS-EGFR- POA showed similar performance. By combination of TAA and POA, the multi-region combined RS (RS-EGFR-Com) achieved the highest prediction performance, with AUCs of 0.896, 0.856, and 0.889 in the primary training, internal validation, and external validation cohort, respectively. For predicting response to EGFR-TKI, the multi-region combined RS (RS-TKI-Com) generated the highest AUCs in the primary training (AUC = 0.817), internal validation (AUC = 0.788), and external validation (AUC = 0.808) cohort, respectively.
CONCLUSIONS: Our findings suggested values of multiregional radiomics of BM for predicting EGFR mutations and response to EGFR-TKI.
CLINICAL RELEVANCE STATEMENT: The application of radiomic analysis of multiparametric brain MRI has proven to be a promising tool to stratify which patients can benefit from EGFR-TKI therapy and to facilitate the precise therapeutics of NSCLC patients with brain metastases.
KEY POINTS: • Multiregional radiomics can improve efficacy in predicting therapeutic response to EGFR-TKI therapy in NSCLC patients with brain metastasis. • The tumor active area (TAA) and peritumoral edema area (POA) may hold complementary information related to the therapeutic response to EGFR-TKI. • The developed multi-region combined radiomics signature achieved the best predictive performance and may be considered as a potential tool for predicting response to EGFR-TKI.
引用
- Fan, Wang, Dong, et al. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC. Eur Radiol. 2023. PMID: 37142868. doi:10.1007/s00330-023-09709-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。